← Eichor
Study identifier: NCT07383766 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Aesthetic Improvement of Facial Rhytids Using Injectables

Condition: Aesthetic  ·  Sponsor: Erevna Innovations Inc.

PhasePhase 4
Planned participants14
Who can joinAll sexes, 30 Years to 75 Years
Healthy volunteersYes

About this study

Revanesse® Renew™+ (Prollenium Medical Technologies Inc.) is a non-crosslinked HA skin booster that combines low- and high-molecular-weight HA at a concentration of 14 mg/mL in a sterile aqueous gel for intradermal injection7. This dual-weight formulation provides both rapid hydration and sustained moisture retention, improving dermal suppleness and promoting subtle textural refinement through physiologic hydration rather than volumization. The present study is designed to compare biweekly and monthly treatment schedules of Revanesse® Renew™+, assessing clinical efficacy, objective biophysical markers, and participant-reported outcomes to inform evidence-based treatment protocols in aesthetic medicine.

This description comes directly from the study's public registry record.

Talk to the study team

Laura Raco, MSc  ·  514-488-0163  ·  lraco@vicpark.com

Always discuss trial participation with your own doctor first.

Locations (1)

Erevna Innovations Inc.Montreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07383766